[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Meshalkin Research Institute of Pathology of Circulation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":169},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,55,88,118,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100626363","phase-3-apixaban-vs-warfarin-in-af-pts-first-three-months-after-repair-or-bio-avr-mvr-100626363",false,"NCT07434661","Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR","Safety and Efficacy of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in the First Three Months After Mitral or Aortic Biological Valve Replacement or Repair","SAFE-HEART","Inclusion Criteria:\n\n* Age ≥18 years at the time of enrolment\n* Open heart aortic or mitral valve repair or biological valve replacement in the last 10 days\n* Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),\n* Informed consent from either the patient or a substitute decision-maker.\n\nExclusion Criteria:\n\n* Mechanical valve replacement\n* Antiphospholipid syndrome (triple positive)\n* Severe renal failure (Cockcroft-Gault equation; creatinine clearance \\\u003C15 ml\u002Fmin)\n* Known significant liver disease (Child-Pugh classification B and C)\n* Left ventricular thrombus\n* Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis\n* Known contraindication for any DOAC or VKA\n* Women who are pregnant, breastfeeding, or of childbearing potential\n* Follow-up not possible","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","SAFE-HEART is a single-centre, randomized controlled trial comparing the safety and efficiency of Apixaban versus Warfarin in the early period (3 months) after repair or bioprosthetics of the mitral and aortic valve cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.",[27,28,29,30,31,32,33],"Valve Disease, Heart","Atrial Fibrillation (AF)","Valve Replacement Surgery","Aortic Valve Surgery","Mitral Valve Annuloplasty","Mitral Valve Repair","Mitral Valve Surgery",[35,36,37,38,39,40,41],"anticoagulation","bioprosthetics","atrial fibrillation","mitral valve repair","aortic valve repair","Apixaban","Warfarin","NOT_YET_RECRUITING","2026-02-20",{"date":45,"type":46},"2026-02-25","ACTUAL",{"date":48,"type":21},"2026-02",{"date":50,"type":21},"2029-01",{"name":52,"class":53},"Meshalkin Research Institute of Pathology of Circulation","NETWORK",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":67,"conditions":68,"keywords":74,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":54},"100621559","left-bundle-branch-pacing-in-patients-with-hypertrophic-cardiomyopathy-after-myectomy-100621559","NCT07372196","Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy","LEFTpaceHCM","Inclusion criteria:\n\n* Men and women aged 18 years and older;\n* Patients with post-myectomy HCM who develop LBBB with a QRS complex greater than 130 ms and a high risk of SCD (HCM Risk-SCD ≥ 6%);\n* Signed informed consent to participate in the study;\n\nExclusion criteria:\n\n* Absence of QRS complex morphology consistent with LBBB in LBBB with a positive QRS complex less than 130 ms;\n* Presence of baseline complete RBBB;\n* Heart transplantation or implantation of an LVAD is planned within the next 6 months;\n* Patients with intermediate or low risk of SCD;\n* History of AMI less than three months prior to study inclusion;\n* Acute renal and hepatic failure;\n* Acute infectious diseases;\n* Presence of mental illness;\n* Presence of other illnesses for which life expectancy is less than one year;\n* Patient refusal to participate in the study at any stage;","75 Years",{"count":64,"type":21},30,[66],"NA","Pilot interventional randomized clinical trial to study the efficacy of left bundle branch pacing in patients with hypertrophic cardiomyopathy after myectomy for the prevention of progression of heart failure, prevent the occurrence of life-threatening rhythm disturbances and promote reverse remodeling of the LV.\n\nThe aim of the study is to evaluate the comparative efficacy and safety of implantation of a cardioverter-defibrillator with left bundle branch block pacing and a dual-chamber cardioverter-defibrillator in patients with HCM and complete left bundle branch block after myectomy at high risk of SCD.\n\nObjectives of the study:\n\n1. To analyze the safety of ICD implantation procedures with LBBB pacing in patients with HCM and LBBB after myectomy at high risk of SCD;\n2. To develop a technique for LBBB lead implantation in patients with HCM and LBBB after myectomy;\n3. To conduct a comparative analysis of QRS complex duration data based on ECG data before and after surgery, LV activation time, and pacing threshold based on postoperative programming data;\n4. To conduct a comparative analysis of the functional class of CHF, NT-proBNP, the presence\u002Fabsence of interventricular and intraventricular dyssynchrony, the degree of diastolic dysfunction, LVEF, and LV EDV based on echocardiography data before and 12 months after surgery;\n5. Conduct a comparative analysis of QRS complex duration data based on ECG data, LV activation time, pacing threshold, the presence of recorded episodes of AF, VT, VF, antitachycardia and shock therapy according to programming data at 3, 6, and 12 months after surgery;\n6. Assess quality of life before and 12 months after surgery using the KCCQ-12 questionnaire; 30 patients (15 patients in each group) will be randomly separated into 2 groups. All participants go through ICD programming at 3, 6, and 12 months after myectomy, assessment of left ventricular remodeling based on ECG and echocardiography, NT-proBNP, assessment of quality of life before surgery and 12 months after surgery.",[69,70,71,72,73],"HCM - Hypertrophic Cardiomyopathy","Sudden Cardiac Death","Left Bundle Branch Pacing","ICD","Heart Failure (HF)",[75,76,71,72,77,78],"sudden cardiac death","Hypertrophic Cardiomyopathy","Heart failure","myectomy","RECRUITING","2026-01-20",{"date":82,"type":46},"2026-01-28",{"date":84,"type":46},"2025-11-14",{"date":86,"type":21},"2027-07-01",{"name":52,"class":53},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":96,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":100,"conditions":101,"keywords":106,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":54},"100521401","radiotherapy-exposed-lung-injury-effect-on-functioning---cohort-100521401","NCT06069115","Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort","Investigation of Oxygen Metabolism and Reserve Capabilities of Cardiovascular and Respiratory Systems in Patients with Malignant Neoplasms of the Breast in the Course of Complex Treatment","RELIEF-COHORT","Inclusion Criteria:\n\n* established diagnosis of malignant breast neoplasm;\n* signed informed voluntary consent of the patient to participate in the study.\n\nExclusion Criteria:\n\n* contraindications to the use of inhaled corticosteroids (presence of active or inactive pulmonary tuberculosis, fungal, viral or bacterial infection of the respiratory organs);\n* lung diseases requiring baseline therapy with glucocorticosteroids (chronic obstructive pulmonary disease, bronchial asthma);\n* mental and\u002For musculoskeletal impairments that make it impossible to adequately perform the exercise test, cooperate with the patient and interpret the results;\n* conditions and diseases requiring emergency surgical intervention and\u002For observation and treatment in an ICU setting;\n* patient's refusal to participate in this clinical trial at any stage of the study.","FEMALE",{"count":98,"type":21},200,"OBSERVATIONAL","Prospective cohort research to study the state of oxygen metabolism, reserve capabilities of cardiovascular and respiratory systems in patients with breast cancer to create a program of prevention and rehabilitation of lung damage in the process of complex treatment of the disease.\n\nThe aim of the study is to study the dynamics of oxygen metabolism and reserve capabilities of cardiovascular and respiratory systems in the process of complex treatment of breast neoplasias.\n\nObjectives of the study:\n\n1. Explore the dynamics of pulmonary ventilation and gas exchange disorders in patients with breast cancer in the course of radiation therapy\n2. Establish an algorithm for risk stratification of post-radiation disorders of pulmonary ventilation and gas exchange in patients with breast cancer.\n3. Analyze the prognostic significance of cardiopulmonary exercise testing in assessing the cardiotoxic effect of chemo- and radiation therapy in patients with breast cancer.\n4. Analyze the influence of post-radiation disorders of pulmonary ventilation and gas exchange on the quality of life and psycho-emotional status of patients with breast cancer.\n5. Develop a fundamental basis for the program of prevention and rehabilitation of post-radiation lung damage in patients with breast neoplasias based on the study of individual parameters of oxygen metabolism and reserve capabilities of cardiovascular and respiratory systems.\n\nAll participants go through 5-week radiation therapy in standard protocol, will have investigation of their lung functioning by spirography and assessment of pulmonary diffusion capacity, cardiopulmonary stress tests and CT-scan on the lungs before radiotherapy course. Researchers will analyze such parameters as stage of the disease, surgery type, all patient's medications, complications, nutritional status, psychological status.",[102,103,104,105],"Breast Neoplasms","Radiation Pneumonia","Radiation Pneumonitis","Radiation Induced Fibrosis",[107,108,109],"breast cancer","radiation therapy","radiation induced lung fibrosis","2025-02-07",{"date":112,"type":46},"2025-02-11",{"date":114,"type":46},"2023-07-18",{"date":116,"type":21},"2026-07-18",{"name":52,"class":53},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":54},"100459018","carotid-revascularization-with-micronet-covered-stent-comparing-early-neurological-outcomes-with-distal-versus-proximal-eps-100459018","NCT05257161","Carotid Revascularization With MicroNet Covered Stent Comparing Early Neurological Outcomes With Distal Versus Proximal EPS","Independent Randomized Clinical Trial in Carotid Revascularization With MicroNet Covered Stent (CGuard) Comparing Early Neurological Outcomes With Distal EPS Versus Proximal EPS","SIBERIA-2","Inclusion Criteria\n\n1. Consecutive patients 45-80 years old accepted for CAS following neurological consultation and qualification for the procedure according to center's routine practice.\n2. More than 6-month life expectancy\n3. Suitable clinical conditions for performing DW-MRI\n4. Written Informed consent approved by the Ethics Committee\n5. Subject agrees to all required follow-up procedures and visits\n\nExclusion Criteria:\n\n1. Currently enrolled in another investigational device or drug study that has not completed the study or that clinically interferes with the current study endpoints\n2. Recent surgical procedure within 30-days before or planned surgery within 30-days after the stenting procedure\n3. Hepatic active disease (bilirubin\\> 35 mmol \u002F l) or renal insufficiency (serum creatinine \\> 2.5 mg\u002FdL or glomerular filtration rate \\\u003C60 ml \u002F min)\n4. Recent evolving acute stroke within 30-days of study evaluation\n5. Myocardial infarction within 72 hours prior to carotid stenting procedure (CPK-MB \\> 3 times normal)\n6. Female patients of childbearing potential or known to be pregnant\n7. Any known factor for potential stroke other than carotid stenosis, such as atrial fibrillation or atrial flutter (paroxysmal, permanent or persistent) or thrombophilia\n8. Patient on VKA or new oral anticoagulants","45 Years","80 Years",{"count":129,"type":21},366,[66],"The SIBERIA study demonstrated a clear advantage of CGuard stent implantation over the existing classical stent when using a distal anti-embolic device. At the same time, there is no Level 1 evidence for a difference between the proximal and distal anti-embolic device for the CGuard stent.",[133,134,135],"Patients With Aterosclerotic Carotid Stenosis","Symptomatic Patients (Stenosis > 50%)","Asymptomatic Patients (Stenosis ≥80%)",[137],"Carotid artery stenting. CGuard stent. Protection Device.","2022-02-16",{"date":140,"type":46},"2022-02-25",{"date":142,"type":46},"2021-11-01",{"date":144,"type":21},"2027-01-01",{"name":52,"class":53},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":155,"targetDuration":157,"studyType":99,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":54},"100320343","international-bifurcation-study-100320343","NCT03450577","International Bifurcation Study","International Prospective Register on Treatment of Coronary Artery Bifurcation Lesions","IBS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Any type of bifurcation lesion in major epicardial artery\n\nExclusion Criteria:\n\n* Patient refused informed consent to participate in the registry","100 Years",{"count":156,"type":21},5000,"5 Years","The IBS registry is an observational, multi-center, real-world registry of stenting in coronary bifurcation lesions that will collect information on procedures and outcomes from various participating centers.\n\nThe aim of this registry is to investigate long-term clinical results and predictors of adverse outcomes after PCI for coronary bifurcation lesions among various participating centers.",[160],"Coronary Bifurcation Lesion","2019-03-07",{"date":163,"type":46},"2019-03-11",{"date":165,"type":46},"2018-01-01",{"date":167,"type":21},"2026-12-31",{"name":52,"class":53},""]